Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep:124:40-7.
doi: 10.1016/j.pbb.2014.05.010. Epub 2014 May 21.

In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection

Affiliations

In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection

R Marshell et al. Pharmacol Biochem Behav. 2014 Sep.

Abstract

Human users of synthetic cannabinoids (SCBs) JWH-018 and JWH-073 typically smoke these drugs, but preclinical studies usually rely on injection for drug delivery. We used the cannabinoid tetrad and drug discrimination to compare in vivo effects of inhaled drugs with injected doses of these two SCBs, as well as with the phytocannabinoid Δ(9)-tetrahydrocannabinol (Δ(9)-THC). Mice inhaled various doses of Δ(9)-THC, JWH-018 or JWH-073, or were injected intraperitoneally (IP) with these same compounds. Rectal temperature, tail flick latency in response to radiant heat, horizontal bar catalepsy, and suppression of locomotor activity were assessed in each animal. In separate studies, mice were trained to discriminate Δ(9)-THC (IP) from saline, and tests were performed with inhaled or injected doses of the SCBs. Both SCBs elicited Δ(9)-THC-like effects across both routes of administration, and effects following inhalation were attenuated by pretreatment with the CB1 antagonist/inverse agonist rimonabant. No cataleptic effects were observed following inhalation, but all compounds induced catalepsy following injection. Injected JWH-018 and JWH-073 fully substituted for Δ(9)-THC, but substitution was partial (JWH-073) or required relatively higher doses (JWH-018) when drugs were inhaled. These studies demonstrate that the SCBs JWH-018 and JWH-073 elicit dose-dependent, CB1 receptor-mediated Δ(9)-THC-like effects in mice when delivered via inhalation or via injection. Across these routes of administration, differences in cataleptic effects and, perhaps, discriminative stimulus effects, may implicate the involvement of active metabolites of these compounds.

Keywords: Antinociception; Behavior; Cannabinoids; Drug discrimination; Hypothermia; Locomotor activity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effects of JWH-018 (filled circles), JWH-073 (open squares), and Δ9-THC (filled triangles) on rectal temperature after intraperitoneal injection (left) or inhalation (center), and comparison of effect-scaled doses of inhaled Δ9-THC (100 mg/30 L), JWH-018 (10 mg/30 L) and JWH-073 (30 mg/30 L) on rectal temperature with (open bars) and without (filled bars) 3 mg/kg rimonabant pretreatment (right). “Air” indicates data obtained from mice placed in the inhalation chamber and exposed to the fan and room air only, while “EtOH” indicates data obtained from mice placed in the inhalation chamber and exposed to combustion of nitrocellulose paper previously treated with the 100% EtOH solution used to dissolve the cannabinoids. Data points in dose-effect curves represent mean ± SEM, and absence of error bars indicate instances where the variability is contained within the point See Results section for statistical comparisons. Bars indicate mean ± SEM, and asterisks indicate significant differences from vehicle-treated EtOH controls by one-way ANOVA and Dunn's test.
Fig. 2
Fig. 2
Effects of JWH-018 (filled circles), JWH-073 (open squares), and Δ9-THC (filled triangles) on locomotor activity after intraperitoneal injection (left) or inhalation (center), and comparison of effect-scaled doses of inhaled Δ9-THC, JWH-018 and JWH-073 on motor activity with (open bars) and without (filled bars) rimonabant pretreatment (right). All other graph properties as described in Fig. 1.
Fig. 3
Fig. 3
Effects of JWH-018 (filled circles), JWH-073 (open squares), and Δ9-THC (filled triangles) on tail flick latency after intraperitoneal injection (left) or inhalation (center), and comparison of effect-scaled doses of inhaled Δ9-THC, JWH-018 and JWH-073 on motor activity with (open bars) and without (filled bars) rimonabant pretreatment (right). All other graph properties as described in Fig. 1.
Fig. 4
Fig. 4
Effects of JWH-018 (filled circles), JWH-073 (open squares), and Δ9-THC (filled triangles) on horizontal bar catalepsy after intraperitoneal injection (left) or inhalation (right). Since no cataleptic effects were observed after inhaled cannabinoids, no tests were performed in the presence of rimonabant pretreatment. All other graph properties as described in Fig. 1.
Fig. 5
Fig. 5
Cataleptic effects of maximal doses of injected Δ9-THC (left) and JWH-018 (middle) yielded similar quantitative data, but the appearances of animals in each condition were qualitatively distinct. All mice injected with JWH-018 exhibited rigid posture and profound leg splay in the hindlimbs, full-body twitches, and handling-induced convulsions, but these effects were not observed following injection of Δ9-THC, even in animals displaying the maximum possible catalepsy score of 30s. Leg splay, twitches and convulsions were blocked in mice treated with 3 mg/kg rimonabant prior to JWH-018 (right, and see Table 1).
Fig. 6
Fig. 6
Δ9-THC-like discriminative stimulus effects of JWH-018 (filled circles) and JWH-073 (open circles), after inhalation (left) or intraperitoneal injection (right). All other graph properties as described in Fig. 1.

Similar articles

Cited by

References

    1. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;160:585–93. - PMC - PubMed
    1. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011;6(7):e21917. - PMC - PubMed
    1. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012;83(7):952–61. - PMC - PubMed
    1. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 2013;346(3):350–61. - PMC - PubMed
    1. Eissenstat MA, Bell MR, D'Ambra TE, Estep KG, Haycock DA, Olefirowicz EM, et al. Aminoalkylindoles (AAIs): structurally novel cannabinoid-mimetics. NIDA Res Monogr. 1990;105:427–8. - PubMed

Publication types